Yujie Zhang

Dr. Yujie Zhang

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
XZXiaopeng Zhou
Xiaopeng Zhou
YTYiqing Tao
Yiqing Tao
CLChengzhen Liang
Chengzhen Liang
YZYujie Zhang
Yujie Zhang
HLHao Li
Hao Li
QCQixin Chen
Qixin Chen
Human mesenchymal stem cells (MSCs) have the potential to differentiate into nucleus pulposus (NP)-like cells under specific stimulatory conditions. Thus far, the effects of bone morphogenetic protein 3 (BMP3) and the cocktail effects of BMP3 and transforming growth factor (TGF)-β on MSC proliferation and differentiation remain obscure. Therefore, this study was designed to clarify these unknowns. MSCs were cultured with various gradients of BMP3 and BMP3/TGF-β, and compared with cultures in basal and TGF-β media. Cell proliferation, glycosaminoglycan (GAG) content, gene expression, and signaling proteins were measured to assess the effects of BMP3 and BMP3/TGF-β on MSCs. Cell number and GAG content increased upon the addition of BMP3 in a dose-dependent manner. The expression of COL2A1, ACAN, SOX9, and KRT19 increased following induction with BMP3 and TGF-β, in contrast to that of COL1A1, ALP, OPN, and COMP. Smad3 phosphorylation was upregulated by BMP3 and TGF-β, but BMP3 did not affect the phosphorylation of extracellular-signal regulated kinase (ERK) 1/2 or c-Jun N-terminal kinase (JNK). Our results reveal that BMP3 enhances MSC proliferation and differentiation into NP-like cells, as indicated by increased cell numbers and specific gene expressions, and may also cooperate with TGF-β induced positive effects. These actions are likely related to the activation of TGF-β signaling pathway.

11 March 2022 in Biomaterials
Verified
Journal Article
Closed access
LYLiwei Ying
Liwei Ying
CLChengzhen Liang
Chengzhen Liang
YZYujie Zhang
Yujie Zhang
JWJingkai Wang
Jingkai Wang
CWChenggui Wang
Chenggui Wang
QCQixin Chen
Qixin Chen

3 September 2021 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
YWYanyan Wang
Yanyan Wang
XGXiaonan Gong
Xiaonan Gong
YZYujie Zhang
Yujie Zhang
Tamoxifen is an estrogen receptor (ER) antagonist that is most commonly used for the treatment of ER-positive breast cancer. However, tamoxifen resistance remains a major cause of cancer recurrence and progression. Here, we aimed to identify hub genes implicated in the progression and prognosis of ER-positive breast cancer following tamoxifen treatment. Microarray data (GSE9893) for 155 tamoxifen-treated primary ER-positive breast cancer samples were obtained from the Gene Expression Omnibus database. In total, 1,706 differentially expressed genes, including 859 upregulated genes and 847 downregulated genes, were identified between relapse samples and relapse-free samples. Weighted correlation network analysis clustered genes into 13 modules, among which the tan and blue modules were the most significantly related to prognosis. From these two modules, we further identified and validated two prognosis-related hub genes (GRSF1 and MAPT) via survival analysis based on several publicly available datasets. High expression of GRSF1 predicted poor prognosis, whereas MAPT indicated favorable outcomes in ER-positive breast cancer. Using breast cancer cell lines and tissue samples, we confirmed that GRSF1 was significantly upregulated and MAPT was downregulated in the tamoxifen-resistant group compared with the tamoxifen-sensitive group. The prognostic value of GRSF1 and MAPT was also verified in 48 tamoxifen-treated ER-positive breast cancer patients in our hospital. Gene set enrichment analysis suggested that GRSF1 was potentially involved in RNA degradation and cell cycle pathways, while MAPT was strongly linked to immune-related signaling pathways. Taken together, our findings established novel prognostic biomarkers to predict tamoxifen sensitivity, which may facilitate individualized management of breast cancer.

4 December 2023 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
XGXiang Gao
Xiang Gao
HLHang Li
Hang Li
DXDeting Xue
Deting Xue
ZPZhijun Pan
Zhijun Pan
YZYujie Zhang
Yujie Zhang
Background: The treatment of Dubberley type B capitellar fractures, which are frequently complicated, is widely debated. This study aimed to investigate the prognostic factors and clinical outcomes of Dubberley type B capitellar fractures treated with Herbert screws combined with posterior buttress plates. Methods: Seven men and nine women (aged 30–68 years) with Dubberley type B capitellar fractures were operated on with Herbert screws combined with posterior buttress plates. The patients were classified into Dubberley types IB (seven), IIB (four), and IIIB (five). Complications and bone union were observed, and functional outcomes were evaluated by the Mayo Elbow Performance Index (MEPI). Results: All patients were followed up for a mean period of 23.5 months (12–30 months). All fractures healed in 8–14 weeks (mean, 10.5 weeks). No cases of non-union, elbow instability, or avascular necrosis occurred. Degenerative arthritis occurred in 7 (44%) and heterotopic ossification in 11 (69%) patients. The median MEPI score was 92.5 (interquartile range, 85–100) points, with 11 reporting excellent, 3 good, and 2 fair outcomes. The MEPI scores of type IIIB fractures were significantly lower than those of types IB and IIB fractures, while the MEPI scores of type IB and IIB fractures did not differ significantly. Conclusions: Dubberley type IIIB capitellar fractures with multiple articular fragments have a poorer prognosis than type IB and IIB fractures. However, Herbert screw fixation combined with posterior metacarpal locking plates is feasible, providing satisfactory recovery of elbow joint function.

6 July 2020 in Research Square
Verified
Preprint
Open access
PDF file
YWYanyan Wang
Yanyan Wang
XGXiaonan Gong
Xiaonan Gong
YZYujie Zhang
Yujie Zhang
Background: The estrogen receptor (ER) antagonist tamoxifen is the most commonly used endocrine therapy for ER-positive breast cancer. However, tamoxifen resistance remains a major cause of cancer recurrence and progression. Here, we aimed to identify hub genes involved in the progression and prognosis of ER-positive breast cancer following tamoxifen treatment.Results: Microarray data (GSE9838) for 155 tamoxifen-treated primary ER-positive breast cancer samples were obtained from the Gene Expression Omnibus database. In total, 1706 differentially expressed genes (DEGs) associated with tamoxifen resistance, including 859 upregulated genes and 847 downregulated genes, were identified. These DEGs were mainly enriched in functions such as protein targeting to the ER and pathways such as ribosome and oxidative phosphorylation.Weighted correlation network analysis (WGCNA) clustered genes into 13 modules, among which the tan and blue modules were the most significantly related to prognosis. From these two modules, we further identified three prognosis-related hub genes (GRSF1, MAPT, and REC8) via survival analysis. High expression ofGRSF1 predicted poor prognosis, whereas MAPT andREC8indicated favorable survival outcomes in all patients with breast cancer and in patients with ER-positive breast cancer based on The Cancer Genome Atlas database. These hub genes were further verified by reverse transcription quantitative polymerase chain reaction.Conclusion: Our findings established novel prognostic biomarkers to predict tamoxifen sensitivity, which may facilitate individualized management of breast cancer.

11 November 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
CYChaorong Yu
Chaorong Yu
YWYanyan Wang
Yanyan Wang
HXHaibin Xu
Haibin Xu
YZYuang Zhang
Yuang Zhang
KWKanbin Wang
Kanbin Wang
YZYujie Zhang
Yujie Zhang
Intervertebral disc degeneration (IVDD) is increasingly recognized as an inflammation-driven disorder in which macrophage infiltration plays a pivotal role. Although metabolic pathways regulate macrophage immune responses, the immunometabolic mechanisms connecting macrophage activation and disc degeneration remain unclear. The sterol regulatory element–binding protein cleavage–activating protein (SCAP) was demonstrated as a key regulator of macrophage inflammatory responses. Using human annulus fibrosus (AF) tissues, a murine AF injury model, and macrophage-specific SCAP-knockout mice, we discovered that SCAP deficiency intensified macrophage pro-inflammatory activation and aggravated IVDD. Metabolomic profiling demonstrated a marked accumulation of 20-hydroxyeicosatetraenoic acid (20-HETE) in SCAP-deficient macrophages. Increased 20-HETE promoted inflammatory cytokine production and lipid peroxidation, whereas pharmacological inhibition of 20-HETE synthesis by HET0016 suppressed these effects and mitigated disc degeneration in vivo. Mechanistically, 20-HETE activated the cyclic GMP–AMP synthase–stimulator of interferon genes (cGAS-STING) pathway and upregulated nuclear receptor coactivator 4 (NCOA4), thereby promoting lipid peroxidation. Silencing NCOA4 or blocking cGAS–STING signaling significantly decreased lipid peroxidation and pro-inflammatory responses. Our work uncovers SCAP downregulation as the initiating event of a 20-HETE-driven immunometabolic axis that links macrophage sterol sensing to redox dysregulation and disc degeneration, thereby revealing a novel metabolic–immune therapeutic target for IVDD.